Document is current
Any future updates will be listed below
-
Authors
Chariou, Paul
Rothstein, Raymond
Miller, Caroline
Kar, Gozde
Johnson, Yoshimi
Connor, Trevor
Malhotra, Kanam
Mitchell, Ngan
Ratiu, Jeremy
Ren, Jun
Harbolick, Elizabeth
Abdourahman, Aicha
Rands, Chris
Shankarapp, Varsha
Yang, Chunning
Boland, Joseph
Mulgrew, Kathy
Dinulescu, Daniela
Mazor, Yariv
Cobbold, Mark
Hollingsworth, Simon
Hammond, Scott
Pollizzi, Kristen
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04995523 at ClinicalTrials.govnct06109779 at ClinicalTrials.govDocuments that mention this clinical trial
470 Multimodal profiling reveals unique and overlapping features of rilvegostomig and PD(x) activity in NSCLC tumor explants
https://doi.org/10.1136/jitc-2025-sitc2025.0470
Safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of AZD2936, a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-experienced advanced/metastatic non-small-cell lung cancer (NSCLC): First report of ARTEMIDE-01.
https://doi.org/10.1200/jco.2023.41.16_suppl.9050
465 Unraveling rilvegostomig’s binding characteristics: TIGIT anchoring increases PD-1 saturation through coordinated engagement
https://doi.org/10.1136/jitc-2025-sitc2025.0465
483 Dual blockage of PD-1 and TIGIT with rilvegostomig inhibits tumor growth in various in vitro/in vivo/ex vivo tumor models through effector CD8 activation and immune modulation
https://doi.org/10.1136/jitc-2024-sitc2024.0483
469 Preclinical studies support clinical development of AZD2936, a monovalent bispecific humanized antibody targeting PD-1 and TIGIT
https://doi.org/10.1136/jitc-2022-sitc2022.0469
nct06357533 at ClinicalTrials.govDocuments that mention this clinical trial
A phase 3, randomized study of adjuvant rilvegostomig plus chemotherapy in resected biliary tract cancer: ARTEMIDE-Biliary01.
https://doi.org/10.1200/jco.2024.42.16_suppl.tps4199
483 Dual blockage of PD-1 and TIGIT with rilvegostomig inhibits tumor growth in various in vitro/in vivo/ex vivo tumor models through effector CD8 activation and immune modulation
https://doi.org/10.1136/jitc-2024-sitc2024.0483
Documents that mention this clinical trial
483 Dual blockage of PD-1 and TIGIT with rilvegostomig inhibits tumor growth in various in vitro/in vivo/ex vivo tumor models through effector CD8 activation and immune modulation
https://doi.org/10.1136/jitc-2024-sitc2024.0483
- License Information
